BioCentury | Feb 26, 2007
Strategy

Hybrigenics escape route

...one USP into the clinic in that time frame. The fate of Hybrigenics Dutch subsidiary, Semaia...
...of the discarded discovery work, hangs in the balance. "We are currently looking at how Semaia...
BioCentury | May 5, 2003
Company News

Hybrigenics SA management update

...Infectious diseases Hired: Rian De Jonge as executive vice president of R&D, formerly CEO of Semaia...
BioCentury | May 5, 2003
Finance

Ebb & Flow

...on signal transduction in cancer. "Semaia had been financed to the tune of about E Semaia's...
...to go," Strosberg said. Hybrigenics will use its technology to identify proteins that interact with Semaia's...
...cancers as well as viral diseases such as AIDS and hepatitis C. Rian De Jonge, Semaia's...
BioCentury | May 5, 2003
Company News

Hybrigenics SA, Semaia BV deal

...Proteomics company Hybrigenics acquired Semaia, which focuses on signal transduction in cancer, in a stock deal...
...in cancer, in a stock deal. Hybrigenics will use its functional proteomics technology to prioritize Semaia's...
...Hybrigenics also will use its protein interaction mapping technology to identify proteins that interact with Semaia's...
BioCentury | Apr 29, 2003
Company News

Hybrigenics acquires Semaia

...Proteomics company Hybrigenics (Paris, France) acquired Semaia (Utrecht, the Netherlands), which focuses on signal transduction in...
...in cancer, in a stock deal. Hybrigenics will use its functional proteomics technology to prioritize Semaia's...
...also will use its protein interaction mapping technology to identify other proteins that interact with Semaia's...
BioCentury | Aug 5, 2002
Finance

Ebb & Flow

...news it will develop and test new antibodies against up to four cancer targets from Semaia...
BioCentury | Aug 5, 2002
Company News

Genmab, Semaia Pharmaceuticals Holding B.V. deal

...to four new validated cancer disease targets from Semaia. Genmab A/S (CSE:GEN; NMarkt:GE9D), Copenhagen, Denmark Semaia...
BioCentury | Jul 31, 2002
Company News

Genmab, Semaia cancer antibody deal

...develop and test new antibodies against up to four new validated cancer disease targets from Semaia...
BioCentury | Feb 11, 2002
Company News

Semaia Pharmaceuticals GmbH & Co. KG management update

Semaia Pharmaceuticals GmbH & Co. KG, Dortmund, Germany Business: Cancer Hired: Thomas Keller as head of research, formerly department head at Novartis AG 's respiratory research center WIR Staff...
BioCentury | Dec 24, 2001
Company News

Semaia Pharmaceuticals Holding B.V., University Medical Center other research news

...million ($1.8 million) grant to identify and validate proteins involved in the etiology of cancer. Semaia...
Items per page:
1 - 10 of 12
BioCentury | Feb 26, 2007
Strategy

Hybrigenics escape route

...one USP into the clinic in that time frame. The fate of Hybrigenics Dutch subsidiary, Semaia...
...of the discarded discovery work, hangs in the balance. "We are currently looking at how Semaia...
BioCentury | May 5, 2003
Company News

Hybrigenics SA management update

...Infectious diseases Hired: Rian De Jonge as executive vice president of R&D, formerly CEO of Semaia...
BioCentury | May 5, 2003
Finance

Ebb & Flow

...on signal transduction in cancer. "Semaia had been financed to the tune of about E Semaia's...
...to go," Strosberg said. Hybrigenics will use its technology to identify proteins that interact with Semaia's...
...cancers as well as viral diseases such as AIDS and hepatitis C. Rian De Jonge, Semaia's...
BioCentury | May 5, 2003
Company News

Hybrigenics SA, Semaia BV deal

...Proteomics company Hybrigenics acquired Semaia, which focuses on signal transduction in cancer, in a stock deal...
...in cancer, in a stock deal. Hybrigenics will use its functional proteomics technology to prioritize Semaia's...
...Hybrigenics also will use its protein interaction mapping technology to identify proteins that interact with Semaia's...
BioCentury | Apr 29, 2003
Company News

Hybrigenics acquires Semaia

...Proteomics company Hybrigenics (Paris, France) acquired Semaia (Utrecht, the Netherlands), which focuses on signal transduction in...
...in cancer, in a stock deal. Hybrigenics will use its functional proteomics technology to prioritize Semaia's...
...also will use its protein interaction mapping technology to identify other proteins that interact with Semaia's...
BioCentury | Aug 5, 2002
Finance

Ebb & Flow

...news it will develop and test new antibodies against up to four cancer targets from Semaia...
BioCentury | Aug 5, 2002
Company News

Genmab, Semaia Pharmaceuticals Holding B.V. deal

...to four new validated cancer disease targets from Semaia. Genmab A/S (CSE:GEN; NMarkt:GE9D), Copenhagen, Denmark Semaia...
BioCentury | Jul 31, 2002
Company News

Genmab, Semaia cancer antibody deal

...develop and test new antibodies against up to four new validated cancer disease targets from Semaia...
BioCentury | Feb 11, 2002
Company News

Semaia Pharmaceuticals GmbH & Co. KG management update

Semaia Pharmaceuticals GmbH & Co. KG, Dortmund, Germany Business: Cancer Hired: Thomas Keller as head of research, formerly department head at Novartis AG 's respiratory research center WIR Staff...
BioCentury | Dec 24, 2001
Company News

Semaia Pharmaceuticals Holding B.V., University Medical Center other research news

...million ($1.8 million) grant to identify and validate proteins involved in the etiology of cancer. Semaia...
Items per page:
1 - 10 of 12